Showing results (431-440 of 454) with videos related to

Sort By:
Pageof 46
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
Blood|June 10, 2023
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendationsKai Rejeski, Marion Subklewe, Mahmoud Aljurf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, et al.
Neurology|May 13, 2021
Primary Progressive Aphasia Associated With GRN Mutations: New Insights Into the Nonamyloid Logopenic VariantDario Saracino, Sophie Ferrieux, Marie Noguès-Lassiaille, et al.
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Hemasphere|May 8, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA groupPierre Sesques, Guillaume Manson, Guillaume Cartron, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 17, 2025
Structural and functional connectivity in tau mutation carriers: from presymptomatic to symptomatic frontotemporal dementiaArabella Bouzigues, Vincent Le Du, Matthieu Joulot, et al.
Journal of Hematology & Oncology|August 6, 2024
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphomaPierre Sesques, Amy A Kirkwood, Mi Kwon, et al.
Blood Advances|August 4, 2025
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II StudyOlivier Tournilhac, Krimo Bouabdallah, Solene Lecolant, et al.
Pageof 46